The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 6, 2008, Pages 2070-2075

  Yun, Cai Hong ^a,b   Mengwasser, Kristen E ^b   Toms, Angela V ^a,b   Woo, Michele S ^b   Greulich, Heidi ^b,d   Wong, Kwok Kin ^b,c   Meyerson, Matthew ^a,b,d   Eck, Michael J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Lung cancer; Tyrosine kinase; X ray crystallography

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ADENOSINE TRIPHOSPHATE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB; LAPATINIB; METHIONINE; THREONINE;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG BINDING; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ANIMALS; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE; ENZYME INHIBITORS; INSECTS; KINETICS; MUTATION; PROTEIN CONFORMATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

PYRONIA TITHONUS;

EID: 40049099220     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0709662105     Document Type: Article

References (40)

1. Paez JG, et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500.
2. Lynch TJ, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139.
3. Pao W, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306-13311.
4. Johnson BE, Janne PA (2005) Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res 65:7525-7529.
5. Gazdar AF, Shigematsu H, Herz J, Minna JD (2004) Mutations and addiction to EGFR: The Achilles "heal" of lung cancers? Trends Mol Med 10:481-486.
6. Chan SK, Gullick WJ, Hill ME (2006) Mutations of the epidermal growth factor receptor in non-small cell lung cancer: Search and destroy. Eur J Cancer 42:17-23.
7. Shigematsu H, Gazdar AF (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118:257-262.
8. Yun CH, et al. (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11:217-227.
9. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125:1137-1149.
10. Carey KD, et al. (2006) Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 66:8163-8171.
11. Sordella R, Bell DW, Haber DA, Settleman J (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Science 305:1163-1167.
12. Sharma SV, et al. (2006) A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10:425-435.
13. Pao W, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73.
14. Kwak EL, et al. (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102:7665-7670.
15. Kobayashi S, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792.
16. Kosaka T, et al. (2006) Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12:5764-5769.
17. Balak MN, et al. (2006) Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12:6494-6501.
18. Greulich H, et al. (2005) Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2:e313.
19. Carter TA, et al. (2005) Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 102:11011-11016.
20. Sequist LV (2007) Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist 12:325-330.
21. Bell DW, et al. (2005) Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 37:1315-1316.
22. Godin-Heymann N, et al. (2007) Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res 67:7319-7326.
23. Regales L, et al. (2007) Development ofnewmouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS ONE 2:e810.
24. Li D, et al. (2007) Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 12:81-93.
25. Kwak EL, et al. (2006) Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res 12:4283-4287.
26. Shah NP, et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125.
27. Roche-Lestienne C, et al. (2002) Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100:1014-1018.
28. Kato JY, et al. (1986) Amino acid substitutions sufficient to convert the nontransforming p60c-src protein to a transforming protein. Mol Cell Biol 6:4155-4160.
29. Yuza Y, et al. (2007) Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biol Ther 6:661-667.
30. Tsou HR, et al. (2005) Optimization of 6,7-disubstituted-4- (arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J Med Chem 48:1107-1131.
31. Stamos J, Sliwkowski MX, Eigenbrot C (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277:46265-46272.
32. Wood ER, et al. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64:6652-6659.
33. Luo L, et al. (2007) ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism. Nat Chem Biol 3:722-726.
34. Otwinowski ZM, Minor W (1997) Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307-326.
35. Read RJ (2001) Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr D 57:1373-1382.
36. Brunger AT, et al. (1998) Crystallography and NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D 54:905-921.
37. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D 60:2126-2132.
38. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D 53:240-255.
39. Schuttelkopf AW, van Aalten DM (2004) PRODRG: A tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D 60:1355-1363.
40. Copeland RA (2000) Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis (Wiley, New York), 2nd Ed, pp 305-317.